TFX Stock Recent News
TFX LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE:TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE:TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE: TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.